Abstract: Oncolytic viruses are administered intratumorally and intravenously. Oncolytic viruses delivered through intravenous injection trend to be eliminated by immune system and fail to exert anti-tumor activity. The anti-immune/tumor effect can be better exerted by using cells carries having lymphocyte characteristics, having stem cell characteristics, having tumor cell characteristics, and transporting oncolytic virus to reach a tumor site.

Key words: cell carries oncolytic virus tumor therapy